Inferra AIResearch Tools

Inferra AI / Company / ALB

Albemarle Corporation

ALB · Materials

Last earnings Aug 5, 2026  ·  Next earnings Nov 4, 2026

Key results

Net incomequarter

$23 million

Net income of $23 million, or ($0.16) per diluted share attributable to common shareholders adjusted diluted earnings per share attributable to common shareholders of $0.11.

SEC original ↗Albemarle Corporation — Earnings release (8-K exhibit)EX-99Jul 30, 2025

Adjusted EPSquarter

$0.16

Net income of $23 million, or ($0.16) per diluted share attributable to common shareholders adjusted diluted earnings per share attributable to common shareholders of $0.11.

SEC original ↗Albemarle Corporation — Earnings release (8-K exhibit)EX-99Jul 30, 2025

Change Net revenuequarter

$ 1,330.0

Second Quarter 2025 Results In millions, except per share amounts Q2 2025 Q2 2024 $ Change % Change Net sales $ 1,330.0 $ 1,430.4 $ (100.4) (7.0) % Net income (loss) attributable to Albemarle Corporation $ 22.9 $ (188.2) $ 211.1 112.2 % Adjusted EBITDA (a) $ 336.5 $ 386.4 $ (49.9) (12.9) % Diluted loss per share attributable to common shareholders $ (0.16) $ (1.96) $ 1.80 91.8 % Non-recurring and other unusual items (a) 0.27 1.99 Adjusted diluted earnings per share attributable to common shareholders (a)(b) $ 0.11 $ 0.04 $ 0.07 175.0 % (a) See Non-GAAP Reconciliations for further details.

SEC original ↗Albemarle Corporation — Earnings release (8-K exhibit)EX-99Jul 30, 2025

Net income attributable to Albemarle of $23 million increased year-over-year by $211 million, due primarily to a prior-year period after-tax charge of $215 million related to capital project asset write-offs and associated contract cancellation costs.

SEC original ↗Albemarle Corporation — Earnings release (8-K exhibit)EX-99Jul 30, 2025

AI analysis

Q2 2025 · reported Jul 30, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Adjusted EPS · Q2 2025
$0.16
EX-99 · Jul 30, 2025
Net income · Q2 2025
$23M
EX-99 · Jul 30, 2025
Change Net revenue · Q2 2025
$ 1,330.0
EX-99 · Jul 30, 2025

Headline figures

MetricQ2 2025Prior qtrYear ago
Net income$23 million——
Adjusted EPS$0.16——
Change Net revenue$ 1,330.0——

EX-99 · Jul 30, 2025

Guidance · company-stated

Direction: Reiterated

Company outlook

“Reducing full-year 2025 capital expenditure outlook to between $650 and $700 million.”

Company outlook

“Maintaining full-year outlook considerations the previously published $9 kg scenario ranges are expected to apply assuming current lithium market pricing persists for the remainder of the year.”

Company outlook

“Other Corporate FY 2025E Capital expenditures $650 - $700 million Depreciation and amortization $630 - $670 million Adjusted effective tax rate (a) (40)% - 25% Corporate costs (b) $40 - $70 million Interest and financing expenses $180 - $210 million Weighted-average common shares outstanding (diluted) 118 million (a) Adjusted effective tax rate dependent on lithium market prices and geographic income mix (b) FY 2025E outlook includes FX impact in the first half of 2025 Cash Flow and Capital Deployment Cash from operations of $538 million in the first half of 2025 increased $73 million compared to the prior-year period.”

Company outlook

“We are reducing our full-year 2025 capital expenditure outlook to between $650 and $700 million.”

Classified from the release's primary full-year outlook statement.

Next earningsNov 4, 2026Verified from the company’s own announcement

Capital allocation

Capex$700M
E capex25%

Reducing full-year 2025 capital expenditure outlook to between $650 and $700 million.

Company-stated claims

Aug 5, 2026

Historical · expanded in both Energy Storage (+229% · ebitda

“Adjusted EBITDA expanded in both Energy Storage (+229%) and Specialties (+61%).”

EX-99 · Aug 5, 2026
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Net income of $23 million, or ($0.16) per diluted share attributable to common shareholders adjusted diluted earnings per share attributable to common shareholders of $0.11

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Direction: Reiterated

Company outlook: “Reducing full-year 2025 capital expenditure outlook to between $650 and $700 million.”

Company outlook: “Maintaining full-year outlook considerations the previously published $9 kg scenario ranges are expected to apply assuming current lithium market pricing persists for the remainder of the year.”

Company outlook: “Other Corporate FY 2025E Capital expenditures $650 - $700 million Depreciation and amortization $630 - $670 million Adjusted effective tax rate (a) (40)% - 25% Corporate costs (b) $40 - $70 million Interest and financing expenses $180 - $210 million Weighted-average common shares outstanding (diluted) 118 million (a) Adjusted effective tax rate dependent on lithium market prices and geographic income mix (b) FY 2025E outlook includes FX impact in the first half of 2025 Cash Flow and Capital Deployment Cash from operations of $538 million in the first half of 2025 increased $73 million compared to the prior-year period.”

Company outlook: “We are reducing our full-year 2025 capital expenditure outlook to between $650 and $700 million.”

Company outlook — Lowered (“Reducing”)
“Reducing full-year 2025 capital expenditure outlook to between $650 and $700 million.”

Company outlook — Reiterated (“Maintaining”)
“Maintaining full-year outlook considerations the previously published $9 kg scenario ranges are expected to apply assuming current lithium market pricing persists for the remainder of the year.”

Company outlook — Reiterated (“maintaining”)
“We delivered strong second quarter results and are maintaining our previous outlook considerations assuming current lithium market pricing persists, said Kent Masters, Chairman and CEO.”

Company outlook — Reiterated (“maintaining”)
“2025 Outlook Considerations Total Corporate Outlook Considerations Albemarle is maintaining its prior full-year outlook considerations for Energy Storage, which are based on observed lithium market price scenarios.”

Company outlook — Reiterated (“unchanged”)
“Ketjen and Specialties outlook considerations are also unchanged.”

Company outlook — Lowered (“lower”)
“Ketjen outlook assumes strong fluidized catalytic cracking (FCC) volume offset by lower clean fuel technologies (CFT) volume due to order timing.”

Company outlook — Raised (“increased”)
“Other Corporate FY 2025E Capital expenditures $650 - $700 million Depreciation and amortization $630 - $670 million Adjusted effective tax rate (a) (40)% - 25% Corporate costs (b) $40 - $70 million Interest and financing expenses $180 - $210 million Weighted-average common shares outstanding (diluted) 118 million (a) Adjusted effective tax rate dependent on lithium market prices and geographic income mix (b) FY 2025E outlook includes FX impact in the first half of 2025 Cash Flow and Capital Deployment Cash from operations of $538 million in the first half of 2025 increased $73 million compared to the prior-year period.”

Company outlook — Lowered (“reducing”)
“We are reducing our full-year 2025 capital expenditure outlook to between $650 and $700 million.”

Company outlook — Lowered (“reductions”)
“Forward-looking statements may include statements regarding our 2025 company and segment outlooks, including expected market pricing of lithium and spodumene and other underlying assumptions and outlook considerations expected capital expenditure amounts and the corresponding impact on cash flow expected impact of tariffs and other trade restrictions market pricing of lithium carbonate equivalent and spodumene plans and expectations regarding other projects and activities, cost reductions and accounting charges, and all other information relating to matters that are not historical facts.”

Classified from the release's primary full-year outlook statement.

Capital allocation

Reducing full-year 2025 capital expenditure outlook to between $650 and $700 million.

SEC original ↗Albemarle Corporation — Earnings release (8-K exhibit)EX-99Jul 30, 2025

Segment FY 2025E Specialties net sales $1.3 - $1.5 billion Specialties adjusted EBITDA $210 - $280 million Ketjen net sales $1.0 - $1.1 billion Ketjen adjusted EBITDA $120 - $150 million Other Corporate Outlook Considerations Albemarle expects its 2025 capital expenditures to be between $650 and $700 million, down approximately 60% from $1.7 billion in 2024.

SEC original ↗Albemarle Corporation — Earnings release (8-K exhibit)EX-99Jul 30, 2025

Other Corporate FY 2025E Capital expenditures $650 - $700 million Depreciation and amortization $630 - $670 million Adjusted effective tax rate (a) (40)% - 25% Corporate costs (b) $40 - $70 million Interest and financing expenses $180 - $210 million Weighted-average common shares outstanding (diluted) 118 million (a) Adjusted effective tax rate dependent on lithium market prices and geographic income mix (b) FY 2025E outlook includes FX impact in the first half of 2025 Cash Flow and Capital Deployment Cash from operations of $538 million in the first half of 2025 increased $73 million compared to the prior-year period.

SEC original ↗Albemarle Corporation — Earnings release (8-K exhibit)EX-99Jul 30, 2025

Capital expenditures of $302 million decreased by $732 million 3 versus the prior-year period, reflecting the impact of decisions that stopped or slowed spending and the completion of capacity expansions in Energy Storage and Specialties.

SEC original ↗Albemarle Corporation — Earnings release (8-K exhibit)EX-99Jul 30, 2025

We are reducing our full-year 2025 capital expenditure outlook to between $650 and $700 million.

SEC original ↗Albemarle Corporation — Earnings release (8-K exhibit)EX-99Jul 30, 2025

Total debt was $3.6 billion, representing a net debt to adjusted EBITDA ratio (as defined in our credit agreement) of approximately 2.3 times.

SEC original ↗Albemarle Corporation — Earnings release (8-K exhibit)EX-99Jul 30, 2025

Strategy & priorities

Adjusted EBITDA of $73 million increased $19 million versus the prior-year quarter due to higher demand and decreased manufacturing costs related to productivity initiatives.

SEC original ↗Albemarle Corporation — Earnings release (8-K exhibit)EX-99Jul 30, 2025

This level of spending reflects in part a timing impact and a continued prioritization on sustaining existing assets and resources.

SEC original ↗Albemarle Corporation — Earnings release (8-K exhibit)EX-99Jul 30, 2025

qualified for discontinued operations treatment at December 31, 2025 because the Company s management did not consider these sales as representing a strategic shift that had or will have a major effect on the Company s operations and financial results.

SEC original ↗Albemarle Corporation — 10-Q Quarterly report10-QAug 5, 2026

The Company s actions regarding Kemerton were part of a broader effort focused on preserving its world-class resource advantages, optimizing its global conversion network, improving the Company s cost competitiveness and efficiency by lowering operating costs, reducing capital intensity and enhancing the Company s financial flexibility.

SEC original ↗Albemarle Corporation — 10-Q Quarterly report10-QAug 5, 2026

Risks & headwinds

Ranges reflect the anticipated direct impact of announced tariffs as of June 30, 2025.

SEC original ↗Albemarle Corporation — Earnings release (8-K exhibit)EX-99Jul 30, 2025

These forward-looking statements, which are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties, often contain words such as anticipate, believe, estimate, expect, guidance, intend, may, outlook, scenario, should, would, and will .

SEC original ↗Albemarle Corporation — Earnings release (8-K exhibit)EX-99Jul 30, 2025

Forward-looking statements may include statements regarding our 2025 company and segment outlooks, including expected market pricing of lithium and spodumene and other underlying assumptions and outlook considerations expected capital expenditure amounts and the corresponding impact on cash flow expected impact of tariffs and other trade restrictions market pricing of lithium carbonate equivalent and spodumene plans and expectations regarding other projects and activities, cost reductions and accounting charges, and all other information relating to matters that are not historical facts.

SEC original ↗Albemarle Corporation — Earnings release (8-K exhibit)EX-99Jul 30, 2025

The non-recurring and unusual items may include acquisition and integration related costs, gains or losses on sales of businesses, restructuring charges, facility divestiture charges, certain litigation and arbitration costs and charges, and other significant non-recurring items.

SEC original ↗Albemarle Corporation — Earnings release (8-K exhibit)EX-99Jul 30, 2025

Legal Proceedings 53 Item 1A.

SEC original ↗Albemarle Corporation — 10-Q Quarterly report10-QAug 5, 2026

Litigation We are involved from time to time in legal proceedings of types regarded as common in our business, including administrative or judicial proceedings seeking remediation under environmental laws, such as the federal Comprehensive Environmental Response, Compensation and Liability Act, commonly known as CERCLA or Superfund, products liability, breach of contract liability and premises liability litigation.

SEC original ↗Albemarle Corporation — 10-Q Quarterly report10-QAug 5, 2026

Competitors

Competitors & peers

Named in the company’s own filings

Rio Tinto (RIO)“Major competitors in lithium compounds include Sociedad Quimica y Minera de Chile S.A., Sichuan Tianqi Lithium, Jiangxi Ganfeng Lithium, Rio Tinto plc, Pilbara Minerals, Tesla and a large number of additional Chinese companies.”Tesla, Inc. (TSLA)“Major competitors in lithium compounds include Sociedad Quimica y Minera de Chile S.A., Sichuan Tianqi Lithium, Jiangxi Ganfeng Lithium, Rio Tinto plc, Pilbara Minerals, Tesla and a large number of additional Chinese companies.”Shell (SHEL)“Our major competitors in the CFT catalysts market include Shell Catalysts & Technologies, Advanced Refining Technologies and Haldor Topsoe.”
Documents

Filings

31 documents

Earnings releases

8 documents

Presentations

0 documents

No presentations for Albemarle Corporation are held in this edition of the library.

Transcripts

0 documents

No transcripts for Albemarle Corporation are held in this edition of the library.

Mentioned by

1 company

Other tracked companies whose held documents mention Albemarle Corporation by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.